Phase 1 N=34 Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
Hepatitis B
Primary: Subjects With Local and/or General Adverse Events Irrespective of Severity — 8; 9; 7; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=32 The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
Keratosis, Actinic
Primary: Difference in the Percentage of Complete Clearance of the Actinic Keratoses — 43; 76; 38; 58 Percentage of AK Clearance
N/A N=60 Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration
Postoperative Pain
Primary: Postoperative Pain Score at Resting — 1; 2 units on a scale — p=0.05
N/A N=402 Post-reimbursement Study to Follow Spinal Neurostimulator Devices for Pain Therapy (French SCS Registry)
Chronic Pain Syndrome
Primary: Percentage of Subjects With at Least 50% Pain Relief in the Area of Predominant Pain at 2 Years — 59.1 Percentage of responders
N/A N=52 Comparison of Supervised and Unsupervised Physical Activity Programs During a Weight Loss Intervention for Adults
Obesity
Primary: Change in Moderate-to-Vigorous Physical Activity (Accumulated in Bouts of at Least 10 Minutes) — 28.0; 25.6; 35.4; 44.4 minutes/day — p=<0.05
N/A N=15 Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Systemic Sclerosis · Scleroderma
Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…
Phase 2 N=8 Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
Infection, Human Immunodeficiency Virus
Primary: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) — 4; 1; 0; 0 Participants
Phase 3 N=862 Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
Migraine
Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days — -2.81; -4.73; -4.57 Days — p=<.001
Phase 1 N=17 Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
Leukaemia, Myelocytic, Acute
Primary: Number of Patients With Severe Toxicities — 1; 0 Participants
Phase 4 N=54 Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab
Rheumatoid Arthritis
Primary: Baseline to Month 3 Change in Total Power Doppler Synovitis Score of 34 Joints (Range 0 - 102) — 6.84 units on a scale
N/A N=10 Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion
Type 1 Diabetes
Primary: Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin — 197; 99 mg/dL
Phase 2 N=46 Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis
Peri-implant Mucositis
Primary: Change in Interleukin 1 B at Base to 24 Hours — -1.075; 1.013 Micrograms per deciliter (ug/dl) — p=0.90
N/A N=55 A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device
Hearing Impairment
Primary: Number of Participants With Skin Erythema After Device Application — 10; 10; 15; 14 Participants
Phase 4 N=246 An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
Neuroendocrine Tumors
Primary: Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths (Core) — 90; 109; 25; 59 Participants
Phase 3 N=774 Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
Bacterial Pneumonia · Community-Acquired Infections
Primary: Number of Participants With Early Clinical Response — 313; 321; 49; 47 Participants